Navigation Links
ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ

BRIARCLIFF MANOR, N.Y., Nov. 30 /PRNewswire/ -- Good Publication Practice 2 (GPP2), a key guidance document for the publication of company-sponsored medical research, has been published online today by the British Medical Journal (BMJ). "The publication of GPP2 in BMJ is strong recognition of the importance of providing support and guidance for industry sponsored research and the publication of study results in the peer-reviewed medical literature," said Chris Graf, Associate Editorial Director, Wiley-Blackwell, lead author of GPP2 and member of the International Society for Medical Publication Professionals (ISMPP) Board of Trustees.

GPP2 is an update of the original Good Publication Practice (GPP) guidelines, which were published in 2003. In light of the increased scrutiny of pharmaceutical company involvement in publications and regulatory changes that have occurred over the past few years, the need to update GPP became readily apparent. ISMPP recognized this need and organized an international steering committee of 14 members who undertook the update. "A key expansion of GPP2 is providing guidance to medical device and biotechnology as well as pharmaceutical companies. More than 25 new recommendations, particularly guidance on the role of the professional medical writer, and two new checklists provide a balanced, up-to-date set of standards," said Yvonne E. Yarker, PhD, ISMPP Board of Trustees, GPP2 coauthor, and Senior Vice President, Medical Communications, Scientific Connexions, a division of KnowledgePoint 360. In addition to the steering committee, GPP2 had input from a large, diverse group of stakeholders. "The consulting process for GPP2 was very extensive with a global review from 116 individuals representing university academic medical centers, medical journal editors and publishers, professional organizations, pharmaceutical, medical device, and biotechnology companies, medical communication agencies, and medical writers," said Dr. Yarker.

Among the most important areas addressed in GPP2 are the responsibilities of authors, reimbursement and honoraria, recommendations for use of publication steering committees and how to assemble them, the role of the professional medical writer, and different types of manuscripts beyond the primary clinical trial results paper.

According to the authors, GPP2 benefits all stakeholders in medical publications - journal editors, publishers, academic universities, companies that conduct medical research, and ultimately patients and the public - through setting standards for adoption that will maintain integrity, completeness, transparency, and responsibility in peer-reviewed publications. GPP2 has been designed to work in concert with other guidelines, such as the International Committee of Medical Journal Editors authorship guidelines and Consolidated Standards of Reporting Trials. The publication includes a checklist that will help those developing medical publications apply the guidelines, and promote transparency and integrity in biomedical writing.

"With publication in the BMJ, and ISMPP taking a lead role in disseminating GPP2, broader adoption of best publication practices is anticipated across medical device, biotechnology, and pharmaceutical industries. Implementing current best publication practices will help promote integrity of medical research reporting within the rapidly evolving current environment," said Mr. Graf.

For more information on GPP2 and to view the publication, go to

About the International Society for Medical Publication Professionals: ISMPP is an independent non-profit professional association with members from the pharmaceutical, medical device, and biotechnology industries; publication planning and medical communication companies; academia; and medical journal staff, including editors and publishers. Its goals are to support the educational needs of publication professionals and to develop best practices that ensure the rigorous maintenance of all ethical standards for reporting results of medical research. Additional information about ISMPP is available by contacting the organization's Executive Director, Kimberly Goldin (phone: 914-945-0507; e-mail:, or online at

This release was issued through eReleases(TM). For more information, visit

SOURCE International Society for Medical Publication Professionals

SOURCE International Society for Medical Publication Professionals
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ISMPP Applauds AAMC Clarification on Ghostwriting Versus Transparent Writing Collaboration in Scientific Publications
2. International Society for Medical Publication Professionals (ISMPP) Announces First CMPP Exam Window Closes, Next Opportunity in September
3. ISMPP Supports Best Practices and Transparency in Medical Publications: Better Understanding of Terms Such as Ghostwriting Needed
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... advised by its major shareholders, Clean Technology Fund I, ... United States based venture capital funds which ... Biorem (on a fully diluted, as converted basis), that ... of their entire equity holdings in Biorem to TUS ...
(Date:6/27/2016)... Diego, CA (PRWEB) , ... June 27, 2016 , ... ... solutions for clinical trials, announced today the Clinical Reach Virtual Patient Encounter ... their care circle with the physician and clinical trial team. , Using the CONSULT ...
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... SAN DIEGO , June 24, 2016 /PRNewswire/ ... that more sensitively detects cancers susceptible to PARP ... individual circulating tumor cells (CTCs). The new test ... of HRD-targeted therapeutics in multiple cancer types. ... therapies targeting DNA damage response pathways, including PARP, ...
Breaking Biology Technology:
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):